Evidence for efficacy of a drug widely used without authorisation in multiple sclerosis: mycophenolate mofetil

@article{Kira2013EvidenceFE,
  title={Evidence for efficacy of a drug widely used without authorisation in multiple sclerosis: mycophenolate mofetil},
  author={J. Kira},
  journal={Journal of Neurology, Neurosurgery \& Psychiatry},
  year={2013},
  volume={85},
  pages={246 - 246}
}
  • J. Kira
  • Published 2013
  • Medicine
  • Journal of Neurology, Neurosurgery & Psychiatry
Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor that has profound immunosuppressive effects on activated T cells, B cells and macrophages. MMF selectively inhibits inosine 5′-monophosphate dehydrogenase type II, responsible for de novo synthesis of the purine nucleotide guanine. The drug has been used for anti-rejection therapy in organ transplantation and also for immunotherapy in a myriad of autoimmune diseases, including refractory multiple sclerosis (MS). The efficacy of… Expand

References

SHOWING 1-9 OF 9 REFERENCES
Mycophenolate Mofetil in Multiple Sclerosis
Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients
Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study
  • M. Etemadifar, M. Kazemi, +4 authors A. Maghzi
  • Medicine
  • Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
  • 2011
A randomized , blinded , parallelgroup , pilot trial of mycophenolate mofetil ( CellCept ) compared with interferon beta - 1 a ( Avonex ) in patients with relapsingremitting multiple sclerosis
  • Ther Adv Neruol Disord
  • 2010
Evidence for ef fi cacy of a drug widely used without authorisation in multiple sclerosis : mycophenolate mofetil